Kim Krmpotic
Acute Care · Phoenix, AZNPI 1427432939
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 72.9% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2023 at $25,008 and has fallen 71.2% since, to $7,198 in 2025. Among acute care clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 459 payments — averaging $171.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$57K
- Atricure, Inc.$14K
- Novartis$1K
- Abbott$871
- Edwards Lifesciences$836
- Endotronix, Inc.$552
- plus $4K from 23 others
What the payments were for
- Consulting fees$15,16919%
- Speaking & faculty fees$34,83144%
- Travel & lodging$8,22010%
- Food & beverage$20,67726%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 221 | $57,490 |
| Atricure, Inc. | 45 | $13,815 |
| Novartis | 78 | $1,389 |
| Abbott | 8 | $871 |
| Edwards Lifesciences | 6 | $836 |
| Endotronix, Inc. | 2 | $552 |
| Amgen | 10 | $426 |
| Johnson & Johnson | 9 | $331 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $299 |
| Medtronic | 5 | $298 |
| Actelion Pharmaceuticals US, Inc. | 6 | $291 |
| Pfizer | 16 | $277 |
| Boehringer Ingelheim | 5 | $256 |
| Impulse Dynamics (USA) Inc. | 2 | $191 |
| Alnylam Pharmaceuticals Inc. | 5 | $182 |
| Sanofi-aventis U.S. LLC | 4 | $171 |
| Biosense Webster, Inc. | 2 | $164 |
| AstraZeneca | 2 | $139 |
| Esperion Therapeutics, Inc. | 1 | $112 |
| Philips North America LLC | 1 | $112 |
| E.r. Squibb & Sons, L.L.C. | 5 | $106 |
| Biotronik Inc. | 3 | $104 |
| Heartflow, Inc. | 1 | $95 |
| Abiomed | 1 | $94 |
| Novo Nordisk | 4 | $88 |
| Merck | 5 | $87 |
| Tactile Systems Technology Inc | 2 | $54 |
| Bayer | 2 | $41 |
| Siemens Medical Solutions USA, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$25,673
- Watchman$11,199
- SYNERGY ABLATION SYSTEM$8,270
- WATCHMAN FLX$6,522
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$5,861
- GENERAL - THERAPIES$3,842
- Farapulse$1,005
- ATRICLIP LAA EXCLUSION SYSTEM$989
- ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM$834
- ATRICURE CRYOICE CRYOABLATION SYSTEM (CRYO2)$643
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$552
- Edwards SAPIEN 3 Transcatheter Heart Valve$459
- CARDIOMEMS$336
- OPTIMIZER$311
- MitraClip$289
- XARELTO$243
- LEQVIO$237
- Repatha$226
- SAPIEN 3 Ultra RESILIA$206
- GENERAL - STRUCTURAL HEART$150
How this compares
$78,897 in reported general payments places this provider in the 95th percentile of 482 acute care providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 137 | $197,358 |
| EntrestoSacubitril/Valsartan | 14 | $22,143 |
| XareltoRivaroxaban | 16 | $20,108 |
| FarxigaDapagliflozin Propanediol | 13 | $13,062 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,610 |
| Dofetilide | 28 | $3,886 |
| SotalolSotalol Hcl | 64 | $1,540 |
| Flecainide Acetate | 21 | $1,533 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 23 | $1,284 |
| Nebivolol Hcl | 12 | $857 |
| Metoprolol Succinate | 65 | $759 |
| Rosuvastatin Calcium | 21 | $482 |
| Lisinopril | 43 | $472 |
| Atorvastatin Calcium | 41 | $386 |
| Metoprolol Tartrate | 56 | $379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $277 | $197,358137 claims |
| NovartisEntresto | $1,389 | $22,14314 claims |
| Johnson & JohnsonXarelto | $331 | $20,10816 claims |
| AstraZenecaFarxiga | $139 | $13,06213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 482 acute care providers in Arizona.
Other acute care in Phoenix
- Laura Cook-GongoraPhoenix$32K
- Cathy PaynePhoenix$26K
- Chandra SorrellePhoenix$16K
- Nicole RauscherPhoenix$12K
- Brooke GambinoPhoenix$11K
- Kelly WesselhoffPhoenix$9K
- Jenna GonzalesPhoenix$8K
- Kristen HudsonPhoenix$8K
- Tammy TyreePhoenix$8K
- Lydia ChongPhoenix$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.